MARKET

ALGS

ALGS

Aligos Therapeutics, Inc.
NASDAQ
0.7500
-0.0431
-5.43%
After Hours: 0.7734 +0.0234 +3.12% 18:00 04/19 EDT
OPEN
0.7700
PREV CLOSE
0.7931
HIGH
0.8000
LOW
0.7300
VOLUME
141.29K
TURNOVER
0
52 WEEK HIGH
1.380
52 WEEK LOW
0.5388
MARKET CAP
56.75M
P/E (TTM)
-0.5497
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ALGS last week (0408-0412)?
Weekly Report · 6d ago
Weekly Report: what happened at ALGS last week (0401-0405)?
Weekly Report · 04/08 09:19
ALIGOS THERAPEUTICS INC - TOPLINE SAFETY AND EFFICACY DATA FROM THIS STUDY ARE EXPECTED IN Q4 2024
Reuters · 04/03 12:00
Mirum’s LIVMARLI receives positive reimbursement recommendation by Canada’s CADTH
Healthcare Mirum’s LIVMARLI receives positive reimbursement recommendation by Canada's CADTH. Mirum Pharmaceuticals, Inc. (MIRM) StockFSV, BSEP, ALGS, IBAT is up 1% in pre-market trading.
Seeking Alpha · 04/02 12:59
Earlier Announced, Aligos Therapeutics Has Been Awarded A $1.3M NIH Contract To Conduct Clinical Development Of A Compound For The Treatment Of Covid-19
Benzinga · 04/01 15:31
Weekly Report: what happened at ALGS last week (0325-0329)?
Weekly Report · 04/01 09:18
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
NASDAQ · 03/27 13:55
Aligos Therapeutics Presents Clinical Data At APASL 2024 From ALG-055009 And ALG-000184 Phase 1 Studies
Aligos Therapeutics, Inc. Is a clinical stage biopharmaceutical company focused on developing novel therapeutics for liver and viral diseases. Aligos will present three oral presentations and one poster presentation at the Asian Pacific Association for the Study of the Liver 2024 in Kyoto, Japan. The company's ALG-055009 is a potential best-in-class small molecule for chronic hepatitis B.
Benzinga · 03/27 12:06
More
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.

Webull offers Aligos Therapeutics Inc stock information, including NASDAQ: ALGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALGS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALGS stock methods without spending real money on the virtual paper trading platform.